Dec 8 (Reuters) - eFFECTOR Therapeutics Inc EFTR.O :
* EFFECTOR THERAPEUTICS ANNOUNCES NEW POSITIVE INTERIM DATA
FROM
DOSE ESCALATION AND PHASE 2 EXPANSION COHORTS OF ZOTATIFIN IN
ER+ METASTATIC BREAST CANCER PATIENTS
* EFFECTOR THERAPEUTICS INC: ZOTATIFIN GENERALLY WELL
TOLERATED AS
DOSE ESCALATION CONTINUES
* EFFECTOR THERAPEUTICS INC- COMPANY EXPECTS TO REPORT
ADDITIONAL
DATA FROM DOSE ESCALATION IN FIRST HALF OF 2024
* EFFECTOR THERAPEUTICS: CURRENTLY ENROLLING AT 0.28 MG/KG
IN ZF
DOUBLET EVALUATING ZOTATIFIN COMBINED WITH FULVESTRANT AND AT
0.1 MG/KG IN ZFA TRIPLET
Source text for Eikon: ID:nGNX4WZjlN
Further company coverage: EFTR.O
((reuters.briefs@thomsonreuters.com;))